Nexien Competitors

Pink Sheets . USA . 
Stock . Nexien Biopharma
NXEN Stock  USD 0.01  0.01  35.00%   
Nexien Biopharma competes with Cannara Biotech, Sonoma Pharmaceuticals, Aquestive Therapeutics, and Evoke Pharma; as well as few others. The company conducts business under Healthcare sector and is part of Drug Manufacturers—Specialty & Generic industry. Analyzing Nexien Biopharma competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Nexien Biopharma to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Nexien Biopharma Correlation with its peers.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Nexien Biopharma competition on your existing holdings.
  
Specify up to 10 symbols:
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Nexien Biopharma's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
0.000.0135.46
Details
Intrinsic
Valuation
LowRealHigh
0.000.0135.46
Details
Naive
Forecast
LowNextHigh
0.00040.0235.47
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
-0.00250.030.06
Details

Nexien Biopharma Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Nexien Biopharma and its competitors represents the degree of relationship between the price movements of corresponding pink sheets. A correlation of about +1.0 implies that the price of Nexien and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Nexien Biopharma does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio
High positive correlations   
CHOOF
+ 0.67
EDXC
SNOA
+ 0.65
CHOOF
LOVFF
+ 0.64
EDXC
UNRV
+ 0.6
SNOA
LOVFF
+ 0.54
CHOOF
UNRV
+ 0.5
CHOOF
  
High negative correlations   
MSMY
- 0.49
CHOOF
AQST
- 0.43
CHOOF
AQST
- 0.38
EDXC
MSMY
- 0.37
EDXC
UNRV
- 0.3
CANN
GSAC
- 0.28
SNOA

Risk-Adjusted Indicators

There is a big difference between Nexien Pink Sheet performing well and Nexien Biopharma Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Nexien Biopharma's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
EDXC  6.12 (0.06) 0.00  0.17  0.00 
 0.00 
 15.38 
(14.53)
 32.23 
CHOOF  0.00  0.00  0.00  0.00  0.00 
 0.00 
 0.00 
 0.00 
 0.00 
CANN  5.55 (0.36) 0.00  0.29  0.00 
 0.00 
 11.47 
(12.08)
 44.14 
CVSI  4.10 (0.05) 0.00  0.07  6.56 
(19.42)
 25.00 
(20.00)
 45.00 
LOVFF  2.54  0.28  0.00 (0.10) 4.38 
(7.77)
 8.51 
(6.90)
 36.67 
SNOA  5.41 (0.70) 0.00 (0.17) 0.00 
 0.00 
 13.88 
(13.23)
 40.82 
MSMY  6.66  0.44  0.03  0.55  7.42 
(18.90)
 16.67 
(14.29)
 58.33 
UNRV  1.51  0.16  0.00  0.34  0.00 
 0.00 
 0.00 
 0.00 
 83.33 
GSAC  11.20  2.04  0.07 (1.07) 11.12 
(32.64)
 33.33 
(25.00)
 58.33 
AQST  3.34  0.00  0.02  0.12  3.80 
(3.56)
 6.51 
(7.14)
 20.28 
All Fundamental Data

Nexien Biopharma Competitive Analysis

The better you understand Nexien Biopharma competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Nexien Biopharma's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Nexien Biopharma's competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
NXEN EDXC CANN CVSI LOVFF SNOA MSMY UNRV GSAC AQST
 35.00 
 0.01 
Nexien
 3.64 
 0.01 
Endexx
 7.61 
 0.04 
General
 0.25 
 0.04 
CVSI
 3.85 
 0.54 
Cannara
 0.34 
 2.92 
Sonoma
 12.50 
 0.0007 
MSMY
 0.00 
 0.02 
Unrivaled
 33.33 
 0.0004 
GelStat
 5.74 
 5.16 
Aquestive
Market Volatility
(90 Days Market Risk)
Out of control
Out of control
Out of control
Out of control
Out of control
Dangerous
Out of control
Very steady
Out of control
Unstable
Market Performance
(90 Days Performance)
OK
Very Weak
Very Weak
Very Weak
Weak
Weak
Insignificant
Very Weak
OK
Insignificant
Odds of Financial Distress
(Probability Of Bankruptcy)
High
Below Average
Below Average
Below Average
Low
Very High
High
Dangerous
Low
Below Average
Current Valuation
(Equity Enterprise Value)
Fairly Valued
Over Valued
Fairly Valued
Over Valued
Over Valued
Fairly Valued
Over Valued
Over Valued
Over Valued
Over Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Not Available
Not Available
Not Available
Not Available
Strong Buy
Not Available
Not Available
Not Available
Strong Buy
Trade Advice
(90 Days Macroaxis Advice)
Sell
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Not Rated
Strong Sell
Strong Sell
Current Ratio
0.51
0.05
0.61
0.93
2.13
3.05
0.06
0.24
0.2
1.47
Net Asset
124.52 K
5.22 M
22.02 M
18.07 M
125.62 M
14.74 M
7.6 K
271.82 M
N/A
57.42 M
Profit Margin
N/A
N/A
-0.59
-0.85
0.0717
-0.36
N/A
-2.82
N/A
-0.6
EBITDA
(563.99 K)
(2.87 M)
(6.6 M)
(14.35 M)
8.14 M
(4.53 M)
(120.69 K)
(31.01 M)
(1.11 M)
1.18 M
Current Valuation
2.58 M
33.07 M
35.32 M
5.53 M
94.03 M
76.38 K
3.09 K
59.15 M
5.1 M
403.93 M
Price To Book
205.41
N/A
2.67
3.57
1.37
0.73
0.19
0.21
N/A
N/A
Operating Margin
N/A
-2.63
-0.0938
-0.93
0.15
-0.35
-3.23
-0.52
-127.79
-0.61
Retained Earnings
N/A
(11.24 M)
(33.4 M)
(21.65 M)
N/A
(194.35 M)
N/A
N/A
(19.46 M)
(319.08 M)
Current Asset
N/A
122 K
1.42 M
15.84 M
N/A
12.89 M
N/A
N/A
920 K
38.38 M
Beta
1.48
1.17
1.09
1.0
1.52
1.38
4.39
3.07
0.47
2.82
Number Of Employees
6
6
77
69
9
10
3
170
2
135
Shares Outstanding
62.77 M
505.16 M
114.17 M
150.1 M
877.48 M
1.34 M
15.44 M
563.59 M
127.45 M
91.18 M
Cash Flow From Operations
(75.14 K)
(1.46 M)
(2.65 M)
(7.49 M)
(6.08 M)
(2.4 M)
(30.64 K)
(18.62 M)
(204.86 K)
(6.38 M)
Annual Yield
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Total Debt
221.73 K
3.37 M
5.91 M
1.4 M
46.19 M
608 K
32.58 K
10.01 M
375.15 K
33.32 M
Return On Equity
-40.7
-12.09
-0.73
-2.36
0.0434
-0.75
N/A
-2.76
-0.27
N/A
Z Score
-8.4
1.4
0.4
2.6
0.6
N/A
-29.52
0.6
5.0
N/A
Return On Asset
-5.99
-0.6
-0.0299
-0.52
0.0327
-0.2
N/A
-0.15
-3.01
-0.16
Book Value Per Share
-0.003
-0.016
0.076
0.009
0.077
7.86
N/A
-0.075
-0.001
-0.5
Number Of Shares Shorted
N/A
N/A
N/A
N/A
N/A
54.67 K
N/A
N/A
N/A
10.14 M
Current Liabilities
N/A
2.46 M
17.93 M
3.01 M
N/A
3.55 M
N/A
N/A
1.61 M
17.95 M
Total Asset
124.52 K
5.22 M
22.02 M
18.07 M
125.62 M
14.74 M
7.6 K
271.82 M
7.1 M
57.42 M
Debt To Equity
0.36
N/A
0.99
0.74
0.49
0.12
N/A
0.65
0.027
468.2
Target Price
N/A
0.05
N/A
0.05
N/A
19.5
N/A
N/A
N/A
10.06
Short Ratio
N/A
N/A
N/A
N/A
N/A
0.22
N/A
N/A
N/A
7.97
Shares Owned By Institutions
N/A
N/A
N/A
N/A
N/A
2.41
N/A
0.007
N/A
55.35
Market Capitalization
1.95 M
26.77 M
18.61 M
7.85 M
63.27 M
3.91 M
18.53 K
12.28 M
5.1 M
444.95 M
Price To Earning
N/A
-10.0
-0.58
54.89
85.0
2.57
N/A
3.93
-0.83
-1.9
Price To Earnings To Growth
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Price To Sales
N/A
19.81
1.23
0.28
1.81
0.31
0.1
0.17
1092.33
7.55
Net Income
(626.36 K)
(4.13 M)
(8.87 M)
(15.55 M)
2.31 M
(4.83 M)
(94.16 K)
(31.27 M)
(475.24 K)
(7.87 M)
Earnings Per Share
-0.013
-0.018
-0.094
-0.13
0.15
-0.99
-0.001
-0.063
-0.001
-0.45
Shares Owned By Insiders
54.17
5.59
82.81
2.01
47.54
1.5
N/A
19.63
9.52
5.0
Revenue
N/A
1.28 M
5.93 M
20.05 M
35.84 M
12.73 M
153.9 K
47.67 M
4.67 K
50.58 M
Working Capital
N/A
(2.34 M)
(16.51 M)
12.83 M
N/A
8.83 M
N/A
N/A
(689 K)
22.66 M
Cash And Equivalents
116.9 K
6.56 K
1.07 M
1.11 M
3.88 M
5.59 M
9.46 K
7.26 M
8.83 K
17.7 M
Cash Per Share
N/A
N/A
0.01
0.01
N/A
1.8
N/A
0.01
N/A
0.33
Gross Profit
N/A
503.01 K
1.49 M
8.62 M
17.33 M
4.48 M
153.9 K
11.97 M
4 K
28.29 M
Day Typical Price
0.0153
0.0105
0.0367
0.0385
0.55
2.92
6.0E-4
0.02
4.0E-4
5.02
Accumulation Distribution
0.35
0.0909
0.12
0.11
0.1
0.0789
0.29
N/A
N/A
0.0795
Market Facilitation Index
0.007
0.001
0.0047
0.0043
0.06
0.24
2.0E-4
N/A
N/A
0.41
Daily Balance Of Power
(1.00)
(0.40)
(0.62)
(0.02)
0.3333
(0.04)
(0.50)
0.0
9.2 T
0.6829
Period Momentum Indicator
(0.01)
(0.0004)
(0)
(0.0001)
0.02
(0.01)
(0.0001)
N/A
1.0E-4
0.28
Rate Of Daily Change
0.65
0.96
0.92
1.0
1.04
1.0
0.88
1.0
1.33
1.06
Day Median Price
0.0165
0.0105
0.0375
0.0378
0.55
2.92
6.0E-4
0.02
4.0E-4
4.96
Price Action Indicator
(0.01)
(0.0001)
(0)
0.0021
N/A
(0.01)
1.0E-4
N/A
1.0E-4
0.35
Relative Strength Index
62.03
48.93
52.02
57.15
89.9
42.54
51.49
11.78
66.17
87.89
Coefficient Of Variation
748.02
(4,338)
(1,276)
10884.45
4197.46
(2,033)
1910.12
2949.89
934.09
1853.66
Mean Deviation
20.42
6.12
5.55
4.1
2.54
5.41
6.66
1.51
11.2
3.34
Jensen Alpha
4.17
(0.06)
(0.36)
(0.05)
0.2781
(0.70)
0.4422
0.1558
2.04
(0)
Total Risk Alpha
(0.84)
(1.51)
(1.82)
(1.40)
(0.78)
(1.68)
(1.17)
(0.93)
(0.88)
(0.44)
Sortino Ratio
0.1269
N/A
N/A
(0)
6.0E-4
N/A
0.0285
N/A
0.0664
0.0233
Downside Variance
1265.98
N/A
N/A
357.15
148.98
N/A
245.69
N/A
665.0
16.62
Standard Deviation
34.74
8.33
7.69
9.37
5.77
8.08
11.03
7.45
17.22
4.18
Kurtosis
6.33
0.7489
1.2
3.24
6.76
2.54
1.82
37.39
0.0277
(0.04)
Potential Upside
59.09
15.38
11.47
25.0
8.51
13.88
16.67
N/A
33.33
6.51
Treynor Ratio
1.21
0.174
0.2882
0.0738
(0.10)
(0.17)
0.5465
0.3369
(1.07)
0.1178
Maximum Drawdown
216.63
32.23
44.14
45.0
36.67
40.82
58.33
83.33
58.33
20.28
Variance
1207.03
69.31
59.18
87.82
33.32
65.21
121.56
55.49
296.51
17.46
Market Risk Adjusted Performance
1.22
0.184
0.2982
0.0838
(0.09)
(0.16)
0.5565
0.3469
(1.06)
0.1278
Risk Adjusted Performance
0.112
(0.01)
(0.05)
0.0162
0.0269
(0.03)
0.0493
0.0349
0.0914
0.0494
Skewness
1.8
(0.37)
(0.17)
0.5469
0.1402
0.3576
0.7342
3.27
0.4717
0.1677
Semi Deviation
19.99
N/A
N/A
6.56
4.38
N/A
7.42
N/A
11.12
3.8
Information Ratio
0.1299
(0.04)
(0.1)
(0)
0.0012
(0.07)
0.0405
0.0164
0.0995
0.0227
Value At Risk
(47.71)
(14.53)
(12.08)
(20.00)
(6.90)
(13.23)
(14.29)
N/A
(25.00)
(7.14)
Expected Short fall
(38.19)
N/A
N/A
(19.42)
(7.77)
N/A
(18.90)
N/A
(32.64)
(3.56)
Downside Deviation
35.58
N/A
N/A
18.9
12.21
N/A
15.67
N/A
25.79
4.08
Semi Variance
399.77
N/A
N/A
43.02
19.17
N/A
55.04
N/A
123.59
14.43

Nexien Biopharma Competition Performance Charts

Five steps to successful analysis of Nexien Biopharma Competition

Nexien Biopharma's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Nexien Biopharma in relation to its competition. Nexien Biopharma's competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Nexien Biopharma in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Nexien Biopharma's competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Nexien Biopharma, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Nexien Biopharma position

In addition to having Nexien Biopharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Petroleum and Natural Gas Thematic Idea Now

Petroleum and Natural Gas
Petroleum and Natural Gas Theme
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Petroleum and Natural Gas theme has 61 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Petroleum and Natural Gas Theme or any other thematic opportunities.
View All  Next Launch

Other Information on Investing in Nexien Pink Sheet

Nexien Biopharma financial ratios help investors to determine whether Nexien Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Nexien with respect to the benefits of owning Nexien Biopharma security.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY